Genentech President Defends Company’s Decision To Embargo Avastin Sales To Compounding Pharmacies

American Academy of Ophthalmology

Susan Desmond-Hellmann, MD, MPH, president of product development for Genentech, said she came to speak at today’s Retina Subspecialty Day program to assure physicians of two things: “One, Genentech will not interfere with your prescribing choice. Two, Genentech will do everything possible to ensure patients have access to Lucentis,” she said.
  • <<
  • >>

Comments